PRECREST: A phase II prevention and biomarker trial of creatine in at-risk huntington disease

Neurology

Volumn 82, Issue 10, 2014, Pages 850-857

  Rosas, Herminia D ^a   Doros, Gheorghe ^a,b   Gevorkian, Sona ^a   Malarick, Keith ^a   Reuter, Martin ^a   Coutu, Jean Philippe ^a,c   Triggs, Tyler D ^a   Wilkens, Paul J ^a   Matson, Wayne ^d   Salat, David H ^a   Hersch, Steven M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^d New England Veterans Administration   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATINE; PLACEBO;

ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; CROSSOVER PROCEDURE; DEPTH PERCEPTION; DIARRHEA; DIFFUSION WEIGHTED IMAGING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; FRACTURE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MEMORY; MENTAL PERFORMANCE; MOTOR PERFORMANCE; NAUSEA; NEPHROLITHIASIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; TREATMENT OUTCOME;

ADULT; ATROPHY; BIOLOGICAL MARKERS; BRAIN; COGNITION DISORDERS; CREATINE; CROSS-OVER STUDIES; DIFFUSION MAGNETIC RESONANCE IMAGING; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HUNTINGTON DISEASE; PRODROMAL SYMPTOMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898712203     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000187     Document Type: Article

References (24)

1. Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 2012;11:42-53.
2. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict- HD study. J Neurol Neurosurg Psychiatry 2008;79:874-880.
3. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 1996;11: 136-142.
4. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
5. Solomon AC, Stout JC, Johnson SA, et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 2007;45:1767-1776.
6. Aretouli E, Brandt J. Episodic memory in dementia: characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases. Arch Clin Neuropsychol 2010;25:396-409.
7. Mohr E, Brouwers P, Claus JJ, Mann UM, Fedio P, Chase TN. Visuospatial cognition in Huntington's disease. Mov Disord 1991;6:127-132.
8. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Withinsubject template estimation for unbiased longitudinal image analysis. Neuroimage 2012;61:1402-1418.
9. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tractbased spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 2006;31:1487-1505.
10. Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006; 66:250-252.
11. Stack EC, Ferrante RJ. Huntington's disease: progress and potential in the field. Expert Opin Investig Drugs 2007; 16:1933-1953.
12. Long JD, Matson WR, Juhl AR, et al. 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 2012;46:625-634.
13. Myers RH. Huntington's disease genetics. NeuroRx 2004; 1:255-262.
14. Hersch S, Jones R, Koroshetz W, Quaid K. The neurogenetics genie: testing for the Huntington's disease mutation. Neurology 1994;44:1369-1373.
15. Bombard Y, Palin J, Friedman JM, et al. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. Am JMed Genet B Neuropsychiatr Genet 2012;159B:217-226.
16. Quaid KA, Sims SL, Swenson MM, et al. Living at risk: concealing risk and preserving hope in Huntington disease. J Genet Couns 2008;17:117-128.
17. Hayden MR, Bombard Y. Psychosocial effects of predictive testing for Huntington's disease. Adv Neurol 2005; 96:226-239.
18. Harper PS, Gevers S, de Wert G, Creighton S, Bombard Y, Hayden MR. Genetic testing and Huntington's disease: issues of employment. Lancet Neurol 2004;3:249-252.
19. Stout JC, Jones R, Labuschagne I, et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 2012;83:687-694.
20. Hersch SM, Rosas HD. Biomarkers to enable the development of neuroprotective therapies for Huntington's disease. In: Lo DC, Hughes RE, editors. Neurobiology of Huntington's Disease: Applications to Drug Discovery. Boca Raton, FL: CRC Press; 2011.
21. Borowsky B, Warner J, Leavitt BR, et al. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 2013;80:1934-1941.
22. Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65:745-747.
23. Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
24. Rosas HD, Lee SY, Bender AC, et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection." Neuroimage 2010;49:2995-3004.